McKesson Corporation $MCK Stock: Calamos Advisors LLC Increases Stake

Calamos Advisors LLC raised its stake in shares of McKesson Corporation (NYSE:MCK) by 2.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,607 shares of the company’s stock after acquiring an additional 618 shares during the period. Calamos Advisors LLC’s holdings in McKesson were worth $26,133,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MCK. Secure Asset Management LLC grew its holdings in McKesson by 484.8% during the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock valued at $1,604,000 after buying an additional 1,760 shares in the last quarter. Royal London Asset Management Ltd. increased its position in shares of McKesson by 1.1% during the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock valued at $84,809,000 after buying an additional 1,216 shares during the period. BayBridge Capital Group LLC lifted its holdings in shares of McKesson by 268.0% in the second quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock worth $1,468,000 after buying an additional 1,415 shares in the last quarter. Benchmark Investment Advisors LLC purchased a new stake in shares of McKesson in the second quarter worth about $441,000. Finally, Summit Global Investments purchased a new stake in shares of McKesson in the second quarter worth about $1,159,000. 85.07% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Bradley Lerman sold 301 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO B Jr sold 111 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares in the company, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,462 shares of company stock valued at $2,511,106 in the last 90 days. 0.06% of the stock is currently owned by insiders.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Down 1.0%

Shares of McKesson stock traded down $11.21 on Friday, reaching $1,060.79. The company’s stock had a trading volume of 812,129 shares, compared to its average volume of 691,239. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,121.50. The firm’s fifty day simple moving average is $938.13 and its two-hundred day simple moving average is $868.12. The company has a market capitalization of $123.68 billion, a price-to-earnings ratio of 27.28, a P/E/G ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. During the same period last year, the firm posted $9.86 earnings per share. McKesson’s revenue was up 7.5% compared to the same quarter last year. As a group, research analysts predict that McKesson Corporation will post 45.26 EPS for the current year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

Wall Street Analyst Weigh In

Several research analysts recently commented on MCK shares. Barclays lifted their target price on shares of McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Royal Bank Of Canada boosted their price target on McKesson from $845.00 to $965.00 and gave the company a “sector perform” rating in a report on Thursday. Mizuho upped their price target on McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday, October 20th. Bank of America increased their price objective on McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Finally, Wells Fargo & Company lifted their price objective on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus price target of $1,026.18.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.